Studies show that even when treating to standards of care for type 2 diabetes (T2D) and cardiovascular disease (CVD), about 1 out of 6 patients may still experience an adverse CV event such as a heart attack or stroke.1
Diabetes treatment guidelines and addressing CV risk
Collaboration and the diabetes care team
Change the course of treatment with Victoza® for your patients with T2D and established CVD
- Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. Diabetes Care. 2006;29:1220-1226.
- Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus. Atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus-mechanisms, management, and clinical considerations. Circulation. 2016;133:2459-2502.
- American Diabetes Association. Standards of medical care in diabetes—2018. Diabetes Care. 2018;41(suppl 1):S1-S172.
- Fruchart J, Davignon J, Hermans MP, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13(26):2-17.
- Victoza [package insert]. Plainsboro, NJ: Novo Nordisk Inc; August 2017.
- American Diabetes Association. Standards of medical care in diabetes-2017. Diabetes Care. 2017;40(suppl 1):S1-S135.
- Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2018 executive summary. Endocr Pract. 2018;24(1):91-120.
- Marso SP, Daniels GH, Brown-Frandsen K, et al; the LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.